JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 21, 2007; DOI: 10.1124/jpet.107.129031

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.129031v1
324/1/1    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
Bonnie Lynne Firestein
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kutzing, M. K.
Right arrow Articles by Firestein, B. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kutzing, M. K.
Right arrow Articles by Firestein, B. L.


Received for publication July 23, 2007.
Revised September 20, 2007.
Accepted for publication September 20, 2007.

Altered Uric Acid Levels and Disease States

Melinda Karen Kutzing 1 Bonnie Lynne Firestein 1*

1 Rutgers, The State University of New Jersey

* Address correspondence to: E-mail: firestein{at}biology.rutgers.edu

Abstract

Altered serum uric acid concentrations, both above and below normal levels, have been linked to a number of disease states. An abnormally high uric acid level has been correlated with gout, hypertension, cardiovascular disease, and renal disease, while a reduced uric acid concentration has been linked to multiple sclerosis, Parkinson's disease, Alzheimer's disease, and optic neuritis. Historically, uric acid has been considered a marker of these disease states. Recent studies, however, have provided evidence that uric acid may actually play a role in the development or progression of such diseases. As a result, the manipulation of uric acid concentrations is now either included in, or being investigated for, the treatment of a variety of disease states.


Key words: cardiovascular, gout, kidney disease, multiple sclerosis, peroxynitrite, uric acid


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
N. Anzai, K. Ichida, P. Jutabha, T. Kimura, E. Babu, C. J. Jin, S. Srivastava, K. Kitamura, I. Hisatome, H. Endou, et al.
Plasma Urate Level Is Directly Regulated by a Voltage-driven Urate Efflux Transporter URATv1 (SLC2A9) in Humans
J. Biol. Chem., October 3, 2008; 283(40): 26834 - 26838.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
P. H. Proctor
Uric Acid and Neuroprotection
Stroke, August 1, 2008; 39(8): e126 - e126.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Bahn, Y. Hagos, S. Reuter, D. Balen, H. Brzica, W. Krick, B. C. Burckhardt, I. Sabolic, and G. Burckhardt
Identification of a New Urate and High Affinity Nicotinate Transporter, hOAT10 (SLC22A13)
J. Biol. Chem., June 13, 2008; 283(24): 16332 - 16341.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.